Tony Coles is a founding investor and the chairman and chief executive officer of Yumanity Therapeutics, a biotechnology company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Dr. Coles was recently named to the National Institutes of Health (NIH) working group tasked with charting the course for President Obama’s Precision Medicine Initiative. He currently serves as chairman and chief executive officer of TRATE Enterprises, LLC; as chairman of the board of CRISPR Therapeutics; and as vice chair of the board of trustees for Johns Hopkins University. Dr. Coles was chairman and chief executive officer of Onyx Pharmaceuticals, Inc. (2008–2012) and president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. (2005–2008). Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Inc. (2002–2005) and held a number of positions of increasing responsibility at Bristol-Myers Squibb Company (1996–2000) and Merck & Co., Inc. (1992–1996). He is based in Cambridge, MA.